The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk

Multiple Sclerosis and Related Disorders

Volumn 4, Issue 4, 2015, Pages 377-379

  Khatri, Bhupendra O ^a   Garland, Jeffery ^b   Berger, Joseph ^c   Kramer, John ^a   Sershon, Lisa ^a   Olapo, Tayo ^a   Sesing, Jean ^a   Dukic, Mary ^a   Rehn, Eileen ^a  

^a Wheaton Franciscan Healthcare   (United States)

^b Wheaton Franciscan Healthcare St Joseph's Hospital   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Lymphocyte counts; PML; RRMS

Indexed keywords

FUMARIC ACID DIMETHYL ESTER; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; INFECTION RISK; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RETROSPECTIVE STUDY; TIME TO TREATMENT; BLOOD; CD4 LYMPHOCYTE COUNT; FOLLOW UP; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CD4 LYMPHOCYTE COUNT; DIMETHYL FUMARATE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84937517128     PISSN: 22110348     EISSN: 22110356     Source Type: Journal    
DOI: 10.1016/j.msard.2015.05.003     Document Type: Article

References (11)

1. J.R. Berger, and K. Khalili The pathogenesis of progressive multifocal leukoencephalopathy Discov. Med. 12 67 2012 495 503
2. U. Ermis, J. Weis, and J.B. Schulz PML in a patient treated with fumaric acid N. Engl. J. Med. 368 17 2013 1657 1658
3. R.J. Fox, D.H. Miller, J.T. Phillips, and et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis N. Engl. J. Med. 367 12 2012 1087 1097
4. (http://www.fda.gov/Drugs/DrugSafety/ucm424625.htm)
5. + cells Drug Saf. 21 2 1999 91 100
6. + cells Drug Saf. 21 2 1999 91 100
7. R. Gold, L. Kappos, D.L. Arnold, and et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis N. Engl. J. Med. 367 12 2012 1098 1107
8. U. Mrowietz, and K. Reich Case reports of PML in patients treated for psoriasis N. Engl. J. Med. 369 11 2013 1080 1081 Sep. 12
9. B.W. van Oosten, J. Killestein, F. Barkhof, C.H. Polman, and M.P. Wattjes PML in a patient treated with dimethyl fumarate from a compounding pharmacy N. Engl. J. Med. 368 17 2013 1658 1659 Apr. 25
10. S.A. Rubant, R.J Ludwig, S Diehl, and et al. Dimethylfumarate reduces leukocyte rolling in vivo through modulation of adhesion molecule expression J. Invest. Dermatol 128 2 2008 326 331
11. + T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate Neurol. Neuroimmunol. Neuroinflamm. 2 2015; 10.1212/NXI.0000000000000076